Atrial Fibrillation Trial, Recruiting NCT06396299 Sponsor: Mahidol University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06396299
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with atrial fibrillation (an irregular heartbeat), confirmed by a heart tracing test (ECG), either in a clinic or through a wearable heart monitor.

Who may not be able to join:

  • People who have had a stroke caused by a blood clot within the last 3 months before joining the trial.
  • People with a low platelet count (a type of blood cell) or certain blood or bone marrow conditions, such as blood clotting disorders or conditions that affect how the blood flows (confirm with trial site).
  • People who have an artificial (mechanical) heart valve.
  • People who have a narrowing of the mitral heart valve caused by rheumatic disease.
  • People who are already taking part in another study where the treatment being given is kept secret.
  • People whose life expectancy is less than 3 years due to another serious illness, such as cancer or AIDS, based on their medical records.
  • People who are pregnant.
  • People who are unable to follow the treatment plan as required by the trial.
  • People who do not agree to take part in the study.
  • People who are currently in hospital or who have been discharged from hospital within the past month.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rungroj Krittayaphong, MD,FESC,FACC, Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol university

Phone: 0815594286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Mahidol University
Registry
ClinicalTrials.gov
Start date
2 June 2024
Est. completion
1 June 2029

Where this trial is recruiting

🇹🇭 Thailand

Primary endpoints

Rate of warfarin and NOACs use; Rate of ischemic stroke/TIA; Rate of systemic embolism; Rate of intracranial hemorrhage; Rate of major bleeding

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov